Trial · NCT00585195
Adverse events11,550
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 11,550Pages stop at row 10,000
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | Low Dose Escalation Cohort: Crizotinib 50 mg QD | 0 | 3 | |
| other | Anaemia | Blood and lymphatic system disorders | Low Dose Escalation Cohort: Crizotinib 100 mg QD | 0 | 4 | |
| other | Anaemia | Blood and lymphatic system disorders | Low Dose Escalation Cohort: Crizotinib 200 mg QD | 2 | 8 | |
| other | Anaemia | Blood and lymphatic system disorders | Low Dose Escalation Cohort: Crizotinib 200 mg BID | 1 | 7 | |
| other | Anaemia | Blood and lymphatic system disorders | Low Dose Escalation Cohort: Crizotinib 250 mg BID | 0 | 8 | |
| other | Anaemia | Blood and lymphatic system disorders | Low Dose Escalation Cohort: Crizotinib 300 mg BID | 1 | 6 | |
| other | Anaemia | Blood and lymphatic system disorders | High Dose Escalation Cohort: Crizotinib 300 mg QD | 2 | 6 | |
| other | Anaemia | Blood and lymphatic system disorders | High Dose Escalation Cohort: Crizotinib 400 mg QD | 1 | 5 | |
| other | Anaemia | Blood and lymphatic system disorders | High Dose Escalation Cohort: Crizotinib 500 mg QD | 0 | 3 | |
| other | Anaemia | Blood and lymphatic system disorders | High Dose Escalation Cohort: Crizotinib 650 mg QD | 1 | 6 | |
| other | Anaemia | Blood and lymphatic system disorders | High Dose Escalation Cohort: Crizotinib 800 mg QD | 3 | 9 | |
| other | Anaemia | Blood and lymphatic system disorders | RP2D Cohort: ROS1-Positive NSCLC: Crizotinib 250 mg | 8 | 53 | |
| other | Anaemia | Blood and lymphatic system disorders | RP2D Cohort: MET Exon 14 Alterations NSCLC: Crizotinib 250 mg | 14 | 85 | |
| other | Anaemia | Blood and lymphatic system disorders | RP2D Cohort: MET Amplification NSCLC: Crizotinib 250 mg | 8 | 41 | |
| other | Anaemia | Blood and lymphatic system disorders | RP2D Cohort: ALK-Negative Cohort 1, NSCLC: Crizotinib 250 mg | 2 | 48 | |
| other | Anaemia | Blood and lymphatic system disorders | RP2D Cohort: ALK-Negative Cohort 2, NSCLC: Crizotinib 250 mg | 2 | 18 | |
| other | Anaemia | Blood and lymphatic system disorders | RP2D Cohort: ALK-Positive Cohort, NSCLC: Crizotinib 250 mg | 17 | 154 | |
| other | Anaemia | Blood and lymphatic system disorders | RP2D Cohort: Enriched Other: Crizotinib 250 mg | 15 | 66 | |
| other | Anaemia | Blood and lymphatic system disorders | Itraconazole Interaction Sub-study: Crizotinib 250 mg | 4 | 18 | |
| other | Anaemia | Blood and lymphatic system disorders | RP2D Cohort: Rifampin Interaction: Crizotinib 250 mg +Rifampin | 4 | 18 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00585195/events